Skip to main content

Advertisement

Log in

Performance of dedicated breast positron emission tomography in the detection of small and low-grade breast cancer

  • Clinical trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose

This study compares the sensitivity of dedicated breast positron emission tomography (DbPET) and whole body positron emission tomography (WBPET) in detecting invasive breast cancer based on tumor size and biology. Further, we explored the relationship between maximum standardized uptake value (SUVmax) of DbPET and biological features of the tumor.

Methods

A total of 639 invasive breast cancer lesions subjected to both DbPET and WBPET before surgery, between January 2016 and May 2019, were included in the study. The sensitivity of DbPET and WBPET in detection and the biology of the tumor according to the clinicopathological features were retrospectively evaluated.

Results

The overall sensitivity of DbPET was higher than that of WBPET (91.4% vs. 80.3%, p < 0.001). Subcentimetric tumors were significant (80.9% vs. 54.3%, p < 0.001). Regardless of the nuclear grade, DbPET could detect more lesions than WBPET. The SUVmax was positively correlated with tumor size (R = 0.395, p < 0.001) and the nuclear grade (p < 0.001). Luminal A-like breast cancer had significantly lower SUVmax values than the other subtypes (p < 0.001).

Conclusions

DbPET is superior to WBPET in the detection of subcentimetric, low-grade breast cancers. Further, by using SUVmax, DbPET can distinguish luminal A-like breast cancer from the other subtypes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

CT:

Computed tomography

DbPET:

Dedicated breast positron emission tomography

ER:

Estrogen receptor

FDG:

18F-fluorodeoxyglucose

FOV:

Field of view

HER2:

Human epidermal growth factor receptor type 2

LBR:

Lesion-to-background ratio

MRI:

Magnetic resonance imaging

PEM:

Positron emission mammography

PET:

Positron emission tomography

ROI:

Region of interest

SUVmax:

Maximum standardized uptake value

WBPET:

Whole body positron emission tomography

References

  1. Welch HG, Prorok PC, O’Malley AJ, Kramer BS (2016) Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness. N Engl J Med 375:1438–1447

    Article  Google Scholar 

  2. Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L (2016) Screening for breast cancer: a systematic review to update the 2009 U.S. preventive services task force recommendation. Ann Intern Med 164:244–255

    Article  Google Scholar 

  3. Ichizawa N, Fukutomi T, Iwamoto E, Akashi-Tanaka S (2002) Long-term results of T1a, T1b and T1c invasive breast carcinomas in Japanese women: validation of the UICC T1 subgroup classification. Jpn J Clin Oncol 32:108–109

    Article  Google Scholar 

  4. Escalona S, Blasco JA, Reza MM, Andradas E, Gómez N (2010) A systematic review of FDG-PET in breast cancer. Med Oncol 27:114–129

    Article  CAS  Google Scholar 

  5. Ohara M, Shigematsu H, Tsutani Y, Emi A, Masumoto N, Ozaki S et al (2013) Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer-usefulness for malignant grade of triple-negative breast cancer. Breast 22:958–963

    Article  Google Scholar 

  6. Sasada S, Masumoto N, Suzuki E, Sueoka S, Goda N, Kajitani K et al (2019) Prediction of biological characteristics of breast cancer using dual-phase FDG PET/CT. Eur J Nucl Med Mol Imaging 46:831–837

    Article  Google Scholar 

  7. Kadoya T, Aogi K, Kiyoto S, Masumoto N, Sugawara Y, Okada M (2013) Role of maximum standardized uptake value in fluorodeoxyglucose positron emission tomography/computed tomography predicts malignancy grade and prognosis of operable breast cancer: a multi-institute study. Breast Cancer Res Treat 141:269–275

    Article  Google Scholar 

  8. Aogi K, Kadoya T, Sugawara Y, Kiyoto S, Shigematsu H, Masumoto N et al (2015) Utility of 18F FDG-PET/CT for predicting prognosis of luminal-type breast cancer. Breast Cancer Res Treat 150:209–217

    Article  CAS  Google Scholar 

  9. Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A (2006) Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 98:267–274

    Article  Google Scholar 

  10. Kanumuri P, Hayse B, Killelea BK, Chagpar AB, Horowitz NR, Lannin DR (2015) Characteristics of multifocal and multicentric breast cancers. Ann Surg Oncol 22:2475–2482

    Article  Google Scholar 

  11. Wolters R, Wöckel A, Janni W, Novopashenny I, Ebner F, Kreienberg R et al (2013) Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients. Breast Cancer Res Treat 142:579–590

    Article  CAS  Google Scholar 

  12. Lynch SP, Lei X, Chavez-MacGregor M, Hsu L, Meric-Bernstam F, Buchhholz TA et al (2012) Multifocality and multicentricity in breast cancer and survival outcomes. Ann Oncol 23:3063–3069

    Article  CAS  Google Scholar 

  13. Yerushalmi R, Kennecke H, Woods R, Olivotto IA, Speers C, Gelmon KA (2009) Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence. Breast Cancer Res Treat 117:365–370

    Article  CAS  Google Scholar 

  14. Ozturk A, Alco G, Sarsenov D, Ilgun S, Ordu C, Koksal U et al (2018) Synchronous and metachronous bilateral breast cancer: a long-term experience. J Boun 23:1591–1600

    Google Scholar 

  15. Michowitz M, Noy S, Lazebnik N, Aladjem D (1985) Bilateral breast cancer. J Surg Oncol 30:109–112

    Article  CAS  Google Scholar 

  16. Gogas J, Markopoulos C, Skandalakis P, Gogas H (1993) Bilateral breast cancer. Am Surg 59:733–735

    CAS  PubMed  Google Scholar 

  17. Tafra L, Cheng Z, Uddo J, Lobrano MB, Stein W, Berg WA et al (2005) Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer. Am J Surg 190:628–632

    Article  Google Scholar 

  18. Yamamoto Y, Ozawa Y, Kubouchi K, Nakamura S, Nakajima Y, Inoue T (2015) Comparative analysis of imaging sensitivity of positron emission mammography and whole-body PET in relation to tumor size. Clin Nucl Med 40:21–25

    Article  Google Scholar 

  19. Berg WA, Weinberg IN, Narayanan D, Lobrano ME, Ross E, Amodei L et al (2006) High-resolution fluorodeoxyglucose positron emission tomography with compression (“positron emission mammography”) is highly accurate in depicting primary breast cancer. Breast J 12:309–323

    Article  Google Scholar 

  20. Nishimatsu K, Nakamoto Y, Miyake K, Ishimori T, Kanao S, Toi M et al (2017) Higher breast cancer conspicuity on dbPET compared to WB-PET/CT. Eur J Radiol 90:138–145

    Article  Google Scholar 

  21. Brierley JD, Gospodararowicz MK, Wittekind C (2016) Union for International Cancer Control (UICC) TNM classification of malignant tumours, 8th Edition. Oxford

  22. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S et al (2010) American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795

    Article  Google Scholar 

  23. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013

    Article  Google Scholar 

  24. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M et al (2015) Tailoring therapies–improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol 26:1533–1546

    Article  CAS  Google Scholar 

  25. Kumar R, Alavi A (2004) Fluorodeoxyglucose-PET in the management of breast cancer. Radiol Clin North Am 42:1113–1122

    Article  Google Scholar 

  26. Hosono M, Saga T, Ito K, Kumita S, Sasaki M, Senda M et al (2014) Clinical practice guideline for dedicated breast PET. Ann Nucl Med 28:597–602

    Article  Google Scholar 

  27. Sasada S, Masumoto N, Goda N, Kajitani K, Emi A, Kadoya T et al (2018) Which type of breast cancers is undetectable on ring-type dedicated breast PET? Clin Imaging 51:186–191

    Article  Google Scholar 

  28. Sasada S, Masumoto N, Kimura Y, Emi A, Kadoya T, Okada M (2020) Classification of abnormal findings on ring-type dedicated breast PET for the detection of breast cancer. Anticancer Res 40:3491–3497

    Article  CAS  Google Scholar 

  29. Duffy SW, Tabár L, Yen AM, Dean PB, Smith RA, Jonsson H et al (2020) Mammography screening reduces rates of advanced and fatal breast cancers: results in 549,091 women. Cancer 126:2971–2979

    Article  Google Scholar 

  30. Moscoso A, Ruibal Á, Domínguez-Prado I, Fernández-Ferreiro A, Herranz M, Albaina L et al (2018) Texture analysis of high-resolution dedicated breast 18 F-FDG PET images correlates with immunohistochemical factors and subtype of breast cancer. Eur J Nucl Med Mol Imaging 45:196–206

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Kazushi Marukawa and Masatsugu Tsujimura of Chuden Hospital for providing data regarding PET examinations.

Funding

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Satoshi Sueoka.

Ethics declarations

Conflicts of interest

The authors declare that they have no conflict of interest.

Ethical approval

The Institutional Review Board approved this study. All procedures performed involving human participants were in accordance with the ethical standards of the institutional research committee and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this retrospective study, the need for formal consent was waived.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sueoka, S., Sasada, S., Masumoto, N. et al. Performance of dedicated breast positron emission tomography in the detection of small and low-grade breast cancer. Breast Cancer Res Treat 187, 125–133 (2021). https://doi.org/10.1007/s10549-020-06088-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-020-06088-1

Keywords

Navigation